| Literature DB >> 33340976 |
Teena D Moody1, Jamie D Feusner2, Nicco Reggente3, Jonathan Vanhoecke2, Mats Holmberg4, Amirhossein Manzouri5, Behzad Sorouri Khorashad5, Ivanka Savic5.
Abstract
Individuals with gender incongruence (GI) experience serious distress due to incongruence between their gender identity and birth-assigned sex. Sociological, cultural, interpersonal, and biological factors are likely contributory, and for some individuals medical treatment such as cross-sex hormone therapy and gender-affirming surgery can be helpful. Cross-sex hormone therapy can be effective for reducing body incongruence, but responses vary, and there is no reliable way to predict therapeutic outcomes. We used clinical and MRI data before cross-sex hormone therapy as features to train a machine learning model to predict individuals' post-therapy body congruence (the degree to which photos of their bodies match their self-identities). Twenty-five trans women and trans men with gender incongruence participated. The model significantly predicted post-therapy body congruence, with the highest predictive features coming from the cingulo-opercular (R2 = 0.41) and fronto-parietal (R2 = 0.30) networks. This study provides evidence that hormone therapy efficacy can be predicted from information collected before therapy, and that patterns of functional brain connectivity may provide insights into body-brain effects of hormones, affecting one's sense of body congruence. Results could help identify the need for personalized therapies in individuals predicted to have low body-self congruence after standard therapy.Entities:
Keywords: Cross-sex hormone therapy; Gender dysphoria; Gender incongruence; LASSO; Machine learning; Prediction; Transgender
Year: 2020 PMID: 33340976 PMCID: PMC7750413 DOI: 10.1016/j.nicl.2020.102517
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1The body morph task asks subjects to rate morphed and unmorphed own-body images. Shown are examples of a front view photograph of a participant who was assigned male sex at birth morphed by 20, 40, 60, 80, and 100% to a photograph of a female (top), and male (bottom) sex-assigned-at-birth cisgender individual. Morphing to same and opposite sex-assigned-at-birth photographs are denoted (arbitrarily) by positive and negative morph degrees, respectively. Note that 100% photographs were unaltered images of another person. The 0% image is the unaltered, unmorphed own-body photograph of the participant.
Fig. 2Analysis flow chart. (A) The average resting-state activity within ROIs from seven functional brain networks defined by Power (30) was used to create a mean BOLD time course. Pairwise Pearson correlations of these time courses resulted in a functional connectivity matrix specific for each network. (B) The lower diagonal of each participant’s network-specific matrix was concatenated with the participant’s pre-therapy clinical features scores to create a feature set for that participant. (C) The LASSO regression model was trained on n − 5 participants’ feature sets and their associated post-therapy body index scores and used to predict each of the left-out participant’s post-therapy body index scores. Left-out participants are denoted as highlighted feature sets (only three shown here). This process was repeated until all participants had been left out in a fold of the cross-validation and had been assigned a predicted post-therapy body index score. We correlated the array of predicted values (ŷ) with the actual values (y), resulting in Pearson’s r, and R2 a measure of our model’s feature-dependent ability to capture the outcome variable variance across participants. Note that due to our participant sample size (n = 25), one-fold of the cross-validation left out five participants.
Demographics, clinical values and ratings of the participants (N = 25).
| Characteristic | Value | SD | P value T-test | P value correlation |
|---|---|---|---|---|
| Trans women/Trans men | 16/9 | |||
| Age | 25.2 | 7.8 | ||
| BMI | 24.1 | 5.5 | ||
| Kinsey scores | 4.0 | 2.0 | ||
| Years of education | 13.3 | 1.9 | ||
| Therapy duration (months) | 14.3 | 5.4 | ||
| Body index pre-therapy short duration trials | −10.4 | 21.8 | ||
| Body index post-therapy short duration trials | −23.1 | 25.7 | p = 0.002 | p < 0.001 |
| Body index pre-therapy long duration trials | −11.1 | 33.5 | ||
| Body index post-therapy long duration trials | −21.3 | 31.7 | p = 0.040* | p < 0.001 |
Negative values of the body index represent (arbitrarily) ratings toward pictures of opposite sex-assigned-at-birth individuals (congruent with sense of self in those diagnosed with gender incongruence).
Paired one-tailed, t-test, comparing pre- versus post-hormone therapy.
Correlation, comparing pre- versus post-hormone therapy.
Associations between predicted post-therapy body congruence for seven brain functional connectivity networks, combined with clinical features, using multivariate analysis.
| Network | R2 Functional connectivity and clinical features | r-value Pearson’s Correlation |
|---|---|---|
| Cingulo-opercular | 0.41* | 0.64* |
| Fronto-parietal | 0.30* | 0.54* |
| Memory Retrieval | 0.20 | 0.45 |
| Salience | 0.19 | 0.43 |
| Dorsal Attention | 0.09 | 0.31 |
| Ventral Attention | 0.06 | 0.24 |
| Default Mode | 0.02 | 0.14 |
| All 7 networks | 0.09 | 0.30 |
| Cingulo-opercular & Fronto-parietal | 0.33* | 0.57 |
Clinical features alone were not significant, R2 = 0.24, r = 0.49. Pearson’s r-values are provided for an estimate of effect sizes. Results are for short-duration trials.
for pbf ≤ 0.006, Bonferroni-corrected significance level.
Fig. 3Associations between the distributions of body index predictions and actual post-therapy values are shown in scatter plots. These LASSO cross-validation models used feature sets that included pre-therapy functional connectivity from the cingulo-opercular network (Left) and the fronto-parietal network (Right), in addition to clinical features. Error bars are standard-errors across the 100 cross-validation predictions for each individual. The Bonferroni-corrected significance level is pbf ≤ 0.006.